View in EDS

1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC.

Saved in:
Bibliographic Details
Title: 1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC.
Authors: Gettinger, S1 (AUTHOR), Beck, T2 (AUTHOR), Yang, X3 (AUTHOR), Telivala, B4 (AUTHOR), Morgensztern, D5 (AUTHOR), Velcheti, V6 (AUTHOR), Ramalingam, S S7 (AUTHOR), Schalper, K8 (AUTHOR), Dajee, M9 (AUTHOR), Ranck, A10 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy292.124